ALLMedicine™ Acromegaly Center

Jan 16th, 2022 - To assess the impact of virtual education programming for patients with acromegaly. We conducted a mixed methods study to evaluate patient attitudes, examine if patient-centered educational forums change these attitudes, and determine the role of ...

Jan 16th, 2022 - Acromegaly is associated with significant morbidity and mortality if not appropriately treated. In addition to insulin-like growth factor 1 (IGF-1) and growth hormone (GH) normalization, and tumor shrinkage, treatment goals include symptom relief,...

Jan 14th, 2022 - To report the effects of pegvisomant (PEGV) treatment on patient-reported outcomes in acromegaly patients. We conducted an extension study of an open-label, multinational, non-interventional study (ACROSTUDY) evaluating the long-term safety and ef...

Jan 13th, 2022 - Octreotide (OCT) is a first-generation somatostatin analog (SSA) used in the treatment of acromegaly and neuroendocrine tumors (NETs). In both diseases, OCT interacts with somatostatin receptors 2 and 5 (SSTR2 and SSTR5), inhibiting hormone hypers...

Jan 11th, 2022 - To describe treatment and long-term outcomes of patients with acromegaly from all health-care regions in Sweden. Analysis of prospectively reported data from the Swedish Pituitary Register of 698 patients (51% females) with acromegaly diagnosed fr...

Feb 26th, 2016 - Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic de...

Feb 26th, 2014 - In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering...

Aug 24th, 2011 - American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.|2011|Katznelson L,Atkinson JL,Cook DM,Ezzat SZ,Hamrahian AH,|diagnosis,therapy,standards,trends,...

Jan 23rd, 2010 - AME Position Statement on clinical management of acromegaly.|2010|Cozzi R,Baldelli R,Colao A,Lasio G,Zini M,|diagnosis,economics,epidemiology,therapy,

Feb 12th, 2009 - The Acromegaly Consensus Group reconvened in November 2007 to update guidelines for acromegaly management. The meeting participants comprised 68 pituitary specialists, including neurosurgeons and endocrinologists with extensive experience treating...

Dec 27th, 2021 - Insulin is the key hormone responsible for regulating the level of glucose in plasma. In several disease states (e.g., obesity, type 2 diabetes, and acromegaly), the target cells are resistant to insulin action. Insulin resistance leads to metabol...

Dec 8th, 2021 - At present there are no recommendations regarding the possibility of discontinuing treatment in cases of recurrent acromegaly with good hormonal control. Discontinuation of treatment is therefore most often decided by the practitioner, on the basi...

Dec 6th, 2021 - The purpose of this trial is to assess the long-term safety of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to contin...

Sep 28th, 2021 - Subjects will be stratified based on prior response to SRL therapy and then randomized to one of three treatment arms. The study will begin when the combination of octreotide LAR or lanreotide and pegvisomant is first administered. Study visits wi...

Sep 9th, 2021 - BACKGROUND AND CLINICAL SIGNIFICANCE Over the past decade, the surgical method for removing pituitary tumors has shifted from a microscopic resection technique performed exclusively by a neurosurgeon, to an endoscopic resection done as a team with...

Jan 10th, 2022 - NEW YORK (Reuters Health) - Many patients with acromegaly may do as well on oral octreotide treatment as they do on injectable somatostatin receptor ligands (iSRLs), an industry-sponsored phase-3 trial suggests. Oral octreotide is the first oral m...

Jan 9th, 2022 - According to new CDC research, COVID-19 is a much greater threat to kids with obesity, with the average length of their hospital stay double that of kids without obesity. (Morbidity and Mortality Weekly Report) A new phase III trial found that ora...

Nov 15th, 2021 - Takeaway Circulating insulin-like growth factor-I (IGF-I) was associated with several common conditions (other than cancer), including a positive association with carpal tunnel syndrome and inverse associations with varicose veins and iron deficie...

Dec 5th, 2020 - Click here to view as PDF. Novartis Leverages Formidable Size and Pipeline to Maintain Strong Oncology Position Novartis—listed on New York, Swiss, and London stock exchanges—was formed in March 1996 by the combination of Sandoz and Ciba-G...

Dec 4th, 2020 - Alexandria Phan, MD The FDA has approved lanreotide (Somatuline Depot Injection) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-...